3. low sodium diet Normal sodium (70mmol/day) plus period: placebo and olive oil 158mmol/24hr 4. low sodium diet Low sodium period: (70mmol/day) plus NaCl 78mmol/24hr tablets (total sodium intake:150mmol/day) with olive oil Key features for bias assessment of randomised trials Citation Method of Allocation Blinding Loss to Use of Ceasing study Reporting all Funding source randomisation concealment follow-up early for benefit outcome where results required Howe et Unclear risk (no Unclear risk (no Participants: 8.2% (but No (unclear No (low risk) Unclear risk Bristol Myers al. (1994) description of description of low risk unclear from risk) (Cholesterol Squibb method of method of which group) reported as (pharmaceutical Providers: low sequence concealment of unclear risk not changing company) – – risk generation) allocation) but exact unclear risk results not Outcome provided) assessors: low risk Summary table
3. low sodium diet (70mmol/day) plus placebo and olive oil 4. low sodium diet (70mmol/day) plus NaCl tablets (total sodium intake:150mmol/day) with olive oil Normal sodium period: 158mmol/24hr Low sodium period: 78mmol/24hr Key features for bias assessment of randomised trials Citation Method of randomisation Allocation concealment Blinding Loss to follow-up Use of where required Ceasing study early for benefit Reporting all outcome results Funding source Howe et al. (1994) Unclear risk (no description of method of sequence generation) Unclear risk (no description of method of concealment of allocation) Participants: low risk Providers: low risk Outcome assessors: low risk 8.2% (but unclear from which group) – unclear risk No (unclear risk) No (low risk) Unclear risk (Cholesterol reported as not changing but exact results not provided) Bristol Myers Squibb (pharmaceutical company) – unclear risk Summary table
Sodium%20Supporting%20Document%201%20%20Systematic%20Literature%20Review.docx